[go: up one dir, main page]

AR021995A1 - Derivados de quinolina 1,2-anelados. - Google Patents

Derivados de quinolina 1,2-anelados.

Info

Publication number
AR021995A1
AR021995A1 ARP990106687A ARP990106687A AR021995A1 AR 021995 A1 AR021995 A1 AR 021995A1 AR P990106687 A ARP990106687 A AR P990106687A AR P990106687 A ARP990106687 A AR P990106687A AR 021995 A1 AR021995 A1 AR 021995A1
Authority
AR
Argentina
Prior art keywords
alkyl
alkyloxy
alkyloxycarbonyl
aryl
mono
Prior art date
Application number
ARP990106687A
Other languages
English (en)
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of AR021995A1 publication Critical patent/AR021995A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Quinoline Compounds (AREA)
  • Information Retrieval, Db Structures And Fs Structures Therefor (AREA)
  • Processing And Handling Of Plastics And Other Materials For Molding In General (AREA)

Abstract

Se relaciona con compuestos de formula (1), las sales de adicion de ácido farmacéuticamente aceptables y las formas estereoquímicamente isoméricas de losmismos, en donde: =X1-X2-X3- es un radical trivalente; >Y1-Y2- es un radical trivalente; r y sso n cada uno independientemente 0 a 5; t es de 0 a 3; cada R1 yR2 son independientemente hidroxi, halo, ciano, alquilo C1-6, trihalometilo, trihalometoxi, alquenilo C2-6, alquiloxi C1-6, hidroxialquiloxi C1-6, alquiltioC1-6, alquiloxi C1-6-alquiloxi C1 -6, alquiloxicarbonilo C1-6, aminoalquiloxi C1-6, mono- o di(alquilo C1-6)amino, mono- o di(alquilo C1-6)aminoalquiloxi C1-6,arilo, arilalquilo C1-6, ariloxi o arilalquiloxi C1-6, hidroxicarbonilo, alquiloxicarbonilo C1-6 o dos R1 o R2en posiciones adyacentes forman juntos unradical bivalente; R3 es hidrogeno, halo, alquilo C1-6, ciano, haloalquilo C1-6, hidroxialquilo C1-6, cianoalquilo C1-6, aminoalquilo C1-6,alquiloxi C1-6-alquilo C1-6, alquiltio C1-6-alquilo C1-6,aminocarbonilalquilo C1-6, hidroxicarbonilo, hidroxicarbonilalquilo C1-6, alquiloxicarbonil C1-6-alquilo C1-6, alquilcarbonil C1-6-alquilo C1-6, alquiloxicarbonilo C1-6, arilo, arilalquiloxi C1-6-alquilo C1-6, mono- o di(alquilo C1-6)aminoalquilo C1- 6; oun radical de formula -O-R10, -S-R10, o -NR11R12; R4 es un imidazolilo opcionalmente sustituido; arilo es un naftalenilo o fenilo opcionalmente sustituido; quetienen actividad inhibitoria de transferasa de geranilgeranilo y transferasa defarnesilo; su preparacion, compos iciones que los contienen y su uso como unamedicina.
ARP990106687A 1998-12-23 1999-12-22 Derivados de quinolina 1,2-anelados. AR021995A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP98204444 1998-12-23

Publications (1)

Publication Number Publication Date
AR021995A1 true AR021995A1 (es) 2002-09-04

Family

ID=8234557

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP990106687A AR021995A1 (es) 1998-12-23 1999-12-22 Derivados de quinolina 1,2-anelados.

Country Status (32)

Country Link
US (2) US6458800B1 (es)
EP (1) EP1140935B1 (es)
JP (1) JP4725940B2 (es)
KR (2) KR100712226B1 (es)
CN (1) CN1178938C (es)
AR (1) AR021995A1 (es)
AT (1) ATE240327T1 (es)
AU (1) AU765437B2 (es)
BG (1) BG65124B1 (es)
BR (1) BR9916827A (es)
CA (1) CA2355717C (es)
CZ (1) CZ302374B6 (es)
DE (1) DE69907964T2 (es)
DK (1) DK1140935T3 (es)
EA (1) EA004542B1 (es)
EE (1) EE04962B1 (es)
ES (1) ES2200591T3 (es)
HK (1) HK1038746B (es)
HR (1) HRP20010454B1 (es)
HU (1) HU229404B1 (es)
ID (1) ID29241A (es)
IL (2) IL143859A0 (es)
NO (1) NO318922B1 (es)
PL (1) PL199080B1 (es)
PT (1) PT1140935E (es)
SI (1) SI1140935T1 (es)
SK (1) SK286072B6 (es)
TR (1) TR200101961T2 (es)
TW (1) TW531533B (es)
UA (1) UA71592C2 (es)
WO (1) WO2000039082A2 (es)
ZA (1) ZA200105136B (es)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1255537T1 (sl) * 2000-02-04 2006-10-31 Janssen Pharmaceutica Nv Inhibitorji farnezil protein transferaze za zdravljenje raka dojk
WO2001062234A2 (en) 2000-02-24 2001-08-30 Janssen Pharmaceutica N.V. Dosing regimen
AU2001252147A1 (en) * 2000-02-29 2001-09-12 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitor combinations
AU2001242434A1 (en) * 2000-02-29 2001-09-12 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitor combinations with vinca alkaloids
AU2001254672A1 (en) * 2000-02-29 2001-09-12 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitor combinations with an her2 antibody
JP2003525235A (ja) * 2000-02-29 2003-08-26 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 抗腫瘍ヌクレオシド誘導体とのファルネシルタンパク質トランスフェラーゼ阻害剤の組み合わせ剤
JP2003525246A (ja) * 2000-02-29 2003-08-26 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 白金化合物とのファルネシルタンパク質トランスフェラーゼ阻害剤の組み合わせ剤
CA2397446A1 (en) * 2000-02-29 2001-09-07 Janssen Pharmaceutica Inc. Combinations of a farnesyl protein transferase inhibitor with nitrogen mustard or nitrosourea alkylating agents
WO2001064252A2 (en) * 2000-02-29 2001-09-07 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitor combinations with further anti-cancer agents
AU2001244167A1 (en) * 2000-02-29 2001-09-12 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitor combinations with anti-tumor anthracycline derivatives
EP1267871A2 (en) * 2000-02-29 2003-01-02 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitor combinations with anti-tumor podophyllotoxin derivatives
AU2001240658A1 (en) * 2000-02-29 2001-09-12 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitor combinations with camptothecin compounds
US20030181473A1 (en) * 2000-02-29 2003-09-25 Palmer Peter Albert Farnesyl protein transferase inhibitor combinations with taxane compounds
JO2361B1 (en) * 2000-06-22 2006-12-12 جانسين فارماسيوتيكا ان. في Enaniumer 1,2-anylated quinoline inhibitor for the transporter - farnesyl
EP1322650B1 (en) * 2000-09-25 2008-09-24 Janssen Pharmaceutica N.V. Farnesyl transferase inhibiting 6-heterocyclylmethyl quinoline and quinazoline derivatives
DE60118225T2 (de) * 2000-09-25 2007-05-03 Janssen Pharmaceutica N.V. Chinolin- und chinazolinderivate und deren verwendung als farnesyl transferase inhibitoren
US7067531B2 (en) 2000-09-25 2006-06-27 Angibaud Patrick Rene Farnesyl transferase inhibiting 6-heterocyclylmethyl quinolinone derivatives
AU2001293829A1 (en) * 2000-09-25 2002-04-02 Janssen Pharmaceutica N.V. Farnesyl transferase inhibiting 6-((substituted phenyl)methyl)-quinoline and quinazoline derivatives
ES2309095T3 (es) 2000-10-02 2008-12-16 Janssen Pharmaceutica Nv Antagonistas de los receptores metabotropicos de glutamato.
DE60139080D1 (de) 2000-11-21 2009-08-06 Janssen Pharmaceutica Nv Farnesyltransferase hemmende benzoheterocyclische derivate
DE60118953T2 (de) * 2000-11-28 2007-01-11 Janssen Pharmaceutica N.V. Farnesyl-protein-transferasehemmer zur behandlung der entzündlichen darmerkrankung
JP4351445B2 (ja) 2000-12-27 2009-10-28 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ファルネシルトランスフェラーゼを阻害する４−置換−キノリンおよびキナゾリン誘導体
ATE415161T1 (de) * 2001-02-15 2008-12-15 Janssen Pharmaceutica Nv Farnesyl-protein-transferase hemmer in kombination mit antiöstrogenen
EP1390033A1 (en) * 2001-04-25 2004-02-25 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitors for treating cachexia
US6740757B2 (en) * 2001-08-29 2004-05-25 Pfizer Inc Enantiomers of 6-[(4-chloro-phenyl)-hydroxy-(3-methyl-3h-imidazol-4-yl)-methyl]-4-[3-(3-hydroxy-3-methyl-but-1-ynyl)-phenyl]-1-methyl-1h-quinolin-2-one and salts thereof, useful in the treatment of cancer
JP2005519876A (ja) * 2001-11-27 2005-07-07 メルク　エンド　カムパニー　インコーポレーテッド ２−アミノキノリン化合物
JP4537710B2 (ja) 2001-12-19 2010-09-08 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ファルネシルトランスフェラーゼ阻害剤としての炭素連結トリアゾールで置換されている１，８−アネル化キノリン誘導体
AU2003223970B2 (en) 2002-03-22 2008-03-06 Janssen Pharmaceutica N.V. Benzylimidazolyl substituted 2-quinoline and quinazoline derivatives for use as farnesyl transferase inhibitors
BR0308945A (pt) * 2002-03-29 2005-01-04 Janssen Pharmaceutica Nv Derivados radiomarcados de quinolina e quinolinona e uso dos mesmos como ligantes para receptores de glutamato metabotrópicos
WO2003087101A1 (en) 2002-04-15 2003-10-23 Janssen Pharmaceutica N.V. Farnesyl transferase inhibiting tricyclic quinazoline derivatives substituted with carbon-linked imidazoles or triazoles
US20030125268A1 (en) * 2002-08-28 2003-07-03 Rybak Mary Ellen Margaret Farnesyl protein transferase inhibitor combinations with anti-tumor anthracycline derivatives
CA2540021A1 (en) 2003-09-26 2005-04-07 Rigel Pharmaceuticals, Inc. Hcv inhibitors and methods of using them
US20050272068A1 (en) * 2004-03-18 2005-12-08 The Brigham And Women's Hospital, Inc. UCH-L1 expression and cancer therapy
WO2006052718A2 (en) 2004-11-05 2006-05-18 Janssen Pharmaceutica N.V. Farnesyltransferase inhibitors for treating sepsis
US20060194821A1 (en) * 2005-02-18 2006-08-31 The Brigham And Women's Hospital, Inc. Compounds inhibiting the aggregation of superoxide dismutase-1
US20060281755A1 (en) * 2005-06-10 2006-12-14 Baumann Christian A Synergistic modulation of flt3 kinase using aminopyrimidines kinase modulators
US20060281769A1 (en) * 2005-06-10 2006-12-14 Baumann Christian A Synergistic modulation of flt3 kinase using thienopyrimidine and thienopyridine kinase modulators
US20060281788A1 (en) * 2005-06-10 2006-12-14 Baumann Christian A Synergistic modulation of flt3 kinase using a flt3 inhibitor and a farnesyl transferase inhibitor
EP2545919A1 (en) 2005-12-23 2013-01-16 Link Medicine Corporation Treatment of synucleinopathies
DE102006012545A1 (de) * 2006-03-18 2007-09-27 Sanofi-Aventis Substituierte 2-Amino-4-phenyl-dihydrochinoline, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, sowie sie enthaltendes Medikament
US8697716B2 (en) 2006-04-20 2014-04-15 Janssen Pharmaceutica Nv Method of inhibiting C-KIT kinase
CA2649736C (en) 2006-04-20 2013-11-26 Janssen Pharmaceutica N.V. Heterocyclic compounds as inhibitors of c-fms kinase
ES2566772T3 (es) 2006-04-20 2016-04-15 Janssen Pharmaceutica, N.V. Inhibidores de la quinasa c-fms
JO3240B1 (ar) 2007-10-17 2018-03-08 Janssen Pharmaceutica Nv c-fms مثبطات كيناز
WO2009151683A2 (en) 2008-03-12 2009-12-17 Link Medicine Corporation Quinolinone farnesyl transferase inhibitors for the treatment of synucleinopathies and other indications
EP2370436A1 (en) 2008-11-13 2011-10-05 Link Medicine Corporation Azaquinolinone derivatives and uses thereof
TW201329025A (zh) 2011-11-01 2013-07-16 Astex Therapeutics Ltd 醫藥化合物
EP2814814B1 (en) * 2012-02-13 2019-05-08 F.Hoffmann-La Roche Ag Imidazolylketone derivatives asd aldosterone synthase inhibitors
JOP20180012A1 (ar) 2012-08-07 2019-01-30 Janssen Pharmaceutica Nv عملية السلفنة باستخدام نونافلوروبوتانيسولفونيل فلوريد
EP2882757B1 (en) 2012-08-07 2016-10-05 Janssen Pharmaceutica, N.V. Process for the preparation of heterocyclic ester derivatives
BR112015008515A2 (pt) 2012-10-16 2017-07-04 Janssen Pharmaceutica Nv moduladores de ror t de quinolinila ligada à heteroarila
WO2014062667A1 (en) 2012-10-16 2014-04-24 Janssen Pharmaceutica Nv Phenyl linked quinolinyl modulators of ror-gamma-t
UY35084A (es) 2012-10-16 2014-04-30 Janssen Pharmaceutica Nv MODULADORES DE RORyt DE QUINOLINILO UNIDOS POR METILENO
US10555941B2 (en) 2013-10-15 2020-02-11 Janssen Pharmaceutica Nv Alkyl linked quinolinyl modulators of RORγt
US9403816B2 (en) 2013-10-15 2016-08-02 Janssen Pharmaceutica Nv Phenyl linked quinolinyl modulators of RORγt
US9221804B2 (en) 2013-10-15 2015-12-29 Janssen Pharmaceutica Nv Secondary alcohol quinolinyl modulators of RORγt
US9284308B2 (en) 2013-10-15 2016-03-15 Janssen Pharmaceutica Nv Methylene linked quinolinyl modulators of RORγt
US9328095B2 (en) 2013-10-15 2016-05-03 Janssen Pharmaceutica Nv Heteroaryl linked quinolinyl modulators of RORgammat
US9346782B2 (en) 2013-10-15 2016-05-24 Janssen Pharmaceutica Nv Alkyl linked quinolinyl modulators of RORγt
EP3057422B1 (en) 2013-10-15 2019-05-15 Janssen Pharmaceutica NV Quinolinyl modulators of ror(gamma)t
US10076512B2 (en) 2014-05-01 2018-09-18 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection
US11311519B2 (en) 2014-05-01 2022-04-26 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection
JP2017536403A (ja) * 2014-12-04 2017-12-07 アイガー・バイオファーマシューティカルズ・インコーポレイテッドＥｉｇｅｒ Ｂｉｏｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． デルタ肝炎ウイルス感染の治療
EP3285768B1 (en) 2015-04-21 2020-12-30 Eiger Biopharmaceuticals, Inc. Pharmaceutical compositions comprising lonafarnib and ritonavir
SI3640345T1 (sl) 2015-08-17 2022-01-31 Kura Oncology, Inc. Postopki za zdravljenje rakavih pacientov z inhibitorji farneziltransferaze
US10745370B2 (en) * 2016-03-23 2020-08-18 Mackay Memorial Hospital Farnesyl transferase inhibitors and uses thereof
EP3534885B1 (en) 2016-11-03 2021-01-20 Kura Oncology, Inc. Farnesyltransferase inhibitors for use in treating cancer

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2002864C (en) 1988-11-29 1999-11-16 Eddy J. E. Freyne (1h-azol-1-ylmethyl) substituted quinoline, quinazoline or quinoxaline derivatives
TW349948B (en) * 1995-10-31 1999-01-11 Janssen Pharmaceutica Nv Farnesyl transferase inhibiting 2-quinolone derivatives
PT865440E (pt) 1995-12-08 2002-09-30 Janssen Pharmaceutica Nv Derivados de (imidazol-5-il)metil-2-quinolinona como inibidores da proteina farnesil transferase
TW591030B (en) 1997-03-10 2004-06-11 Janssen Pharmaceutica Nv Farnesyl transferase inhibiting 1,8-annelated quinolinone derivatives substituted with N- or C-linked imidazoles
RU2205831C2 (ru) * 1997-04-25 2003-06-10 Янссен Фармацевтика Н.В. Хиназолиноны, ингибирующие фарнезилтрансферазу
IL133212A (en) * 1997-06-02 2005-12-18 Janssen Pharmaceutica Nv History of use (imidazolil-5-yl) methyl-2-quinolinone that act as culture inhibitors of smooth muscle cells

Also Published As

Publication number Publication date
IL143859A0 (en) 2002-04-21
ID29241A (id) 2001-08-16
HUP0104582A3 (en) 2002-12-28
HU229404B1 (en) 2013-12-30
KR100712226B1 (ko) 2007-04-27
EA200100708A1 (ru) 2001-12-24
EE200100318A (et) 2002-10-15
EP1140935B1 (en) 2003-05-14
CN1178938C (zh) 2004-12-08
IL143859A (en) 2008-04-13
KR20010087396A (ko) 2001-09-15
EA004542B1 (ru) 2004-06-24
AU2795300A (en) 2000-07-31
US6914066B2 (en) 2005-07-05
TW531533B (en) 2003-05-11
SI1140935T1 (en) 2003-10-31
HUP0104582A2 (hu) 2002-04-29
AU765437B2 (en) 2003-09-18
EP1140935A2 (en) 2001-10-10
BR9916827A (pt) 2001-10-16
WO2000039082A2 (en) 2000-07-06
DE69907964D1 (de) 2003-06-18
CZ302374B6 (cs) 2011-04-20
JP2002533435A (ja) 2002-10-08
US6458800B1 (en) 2002-10-01
WO2000039082A3 (en) 2000-10-26
ES2200591T3 (es) 2004-03-01
NO20013088D0 (no) 2001-06-21
BG105631A (en) 2002-02-28
CZ20012142A3 (cs) 2002-01-16
NO318922B1 (no) 2005-05-23
ATE240327T1 (de) 2003-05-15
CA2355717C (en) 2011-02-08
BG65124B1 (bg) 2007-03-30
HK1038746A1 (en) 2002-03-28
UA71592C2 (uk) 2004-12-15
NO20013088L (no) 2001-06-21
JP4725940B2 (ja) 2011-07-13
SK286072B6 (sk) 2008-02-05
DK1140935T3 (da) 2003-09-01
KR100818541B1 (ko) 2008-04-02
PL199080B1 (pl) 2008-08-29
HRP20010454A2 (en) 2002-06-30
TR200101961T2 (tr) 2001-12-21
ZA200105136B (en) 2002-06-21
SK8732001A3 (en) 2002-02-05
HK1038746B (zh) 2003-09-05
US20030119843A1 (en) 2003-06-26
DE69907964T2 (de) 2004-02-19
CN1331693A (zh) 2002-01-16
PL349504A1 (en) 2002-07-29
CA2355717A1 (en) 2000-07-06
HRP20010454B1 (en) 2004-06-30
KR20060117380A (ko) 2006-11-16
PT1140935E (pt) 2003-10-31
EE04962B1 (et) 2008-02-15

Similar Documents

Publication Publication Date Title
AR021995A1 (es) Derivados de quinolina 1,2-anelados.
TW349948B (en) Farnesyl transferase inhibiting 2-quinolone derivatives
BR0010476A (pt) Compostos derivados do 4,5,6,7-tetrahidroindazol e seu uso como agentes antitumorais
CO5590894A2 (es) Derivados de a-(n-sulfonamido)acetamida como inhibidores del peptido b-amiloideo
HUP0301431A2 (hu) 3-Indolil-4-fenil-1H-pirrol-2,5-dion-származékok, mint glikogén szintáz kináz-3béta inhibitorok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
ID27535A (id) Turunan pirasola sebagai inhibitor p-38 map kinase
BR0211427A (pt) Compostos, processo para preparar os mesmos, composição adequada para combater fungos danosos, uso de compostos, e, processo para combater fungos danosos
ES2140961T3 (es) Nuevos derivados de 19-nor-pregneno.
AR012489A1 (es) Tiofenopiridinas antagonistas del factor de liberacion de corticotropina. procedimiento para su preparacion, el uso de las mismas en la preparacionde un medicamento, composicion farmaceutica que las comprende, procedimiento para la preparacion de dicha composicion, un compuesto intermediario y
NZ231188A (en) Piperidylthieno triazolodiazepine derivatives and pharmaceutical compositions
DE60117847D1 (de) Farnesyltransferase hemmende, in der 4-stellung substituierte chinolin- und chinazolinderivate
AP1555A (en) Derivatives of isosorbid mononitrate, utilization as vasodilator agents with reduced tolerance
ATE61347T1 (de) Zytoprotektive derivate zur anwendung bei ischaemischen erkrankungen, ihre herstellung und sie enthaltende zusammensetzungen.
ES2000481A6 (es) Procecimiento de preparacion de nuevos derivados del dihidro-2,3 benzofurano
HUP0303279A2 (hu) Indolo-pirrolo-karbazolok cukorszármazékai, mint topoizomeráz inhibitorok és ezeket tartalmazó gyógyszerkészítmények
CA2289787A1 (en) Fungicidal mixtures
BG106847A (en) Substituted piperazine derivatives as mtp inhibitors
TW350838B (en) Quinoline derivatives
ES2172294T3 (es) Nuevos derivados del 1-indanol, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
AR041720A1 (es) Derivados de n- benzodioxolilo, n- benzodioxanilo y n- benzodioxepinilarilcarboxamida que pueden usarse para el tratamiento de dislipidemia, y composiciones farmaceuticas que los contienen
DK0514942T3 (da) Hidtil ukendte benzopyranderivater og fremgangsmåder til fremstilling deraf
DE3769284D1 (de) Fungizide cyclohexylamine.
DE60144246D1 (de) Imidazolderivate, verfahren zu deren herstellung und deren verwendung
AR027035A1 (es) Pirroles sustituidos
DE60119383D1 (de) Farnesyltransferasehemmende 4-heterocyclylchinolin- und chinazolinderivate

Legal Events

Date Code Title Description
FG Grant, registration